Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epidermal growth factor receptor targeting.

C McKinnon1

  • 1Current Drugs Ltd, Middlesex House, 34-42 Cleveland Street, London W1P 6LB, United Kingdom. colinm@cursci.co.uk

Idrugs : the Investigational Drugs Journal
|August 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disruption of Transthalamic Circuitry from the Primary Visual Cortex Impairs Visual Discrimination in Mice.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2025
Same author

DISRUPTION OF TRANSTHALAMIC CIRCUITRY FROM PRIMARY VISUAL CORTEX IMPAIRS VISUAL DISCRIMINATION IN MICE.

bioRxiv : the preprint server for biology·2025
Same author

A transthalamic pathway crucial for perception.

bioRxiv : the preprint server for biology·2023
Same author

A feline anaesthetic death associated with equipment incompatibility.

Australian veterinary journal·2019
Same author

Qualitative results of a structured group program for carers of people with frontotemporal dementia.

International journal of geriatric psychiatry·2013
Same author

Clinical evaluation of alfaxalone as an anaesthetic induction agent in cats less than 12 weeks of age.

Australian veterinary journal·2012
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

This research explores targeting the epidermal growth factor receptor (EGFR) in cancer therapy. Studies show that inhibiting EGFR tyrosine kinase (TK) can correlate with reduced tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is frequently overexpressed in various malignancies.
  • Targeting EGFR offers a promising strategy for cancer treatment.
  • EGFR tyrosine kinase (TK) inhibitors and antibodies are key therapeutic agents.

Purpose of the Study:

  • To discuss recent advancements in the marking and detection of EGFR.
  • To review biological studies and Phase I trials of EGFR-targeting compounds.
  • To explore the correlation between EGFR function and growth inhibition in cancer.

Main Methods:

  • Review of biological studies on EGFR.
  • Analysis of Phase I clinical trials involving EGFR tyrosine kinase (TK) inhibitors.

Related Experiment Videos

  • Discussion of detection and marking techniques for EGFR.

    • Main Results:

    • Biological studies confirm the role of EGFR in cancer cell proliferation.
    • Phase I trials demonstrate the feasibility and preliminary efficacy of EGFR TK inhibitors.
    • Established correlations between EGFR overexpression/function and therapeutic response.

    Conclusions:

    • Targeting EGFR, particularly through TK inhibitors, is a validated approach in cancer therapy.
    • Further research into EGFR detection and inhibition holds potential for improved cancer treatments.
    • The efficacy of EGFR-targeted therapies is linked to receptor expression and function.